Advances in the treatment of malignant Gliomas

Current Oncology Reports

Volumn 12, Issue 1, 2010, Pages 26-33

  Khasraw, Mustafa ^a   Lassman, Andrew B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antiangiogenic therapy; Bevacizumab; Glioblastoma; Temozolomide

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CARMUSTINE; CDX 110 VACCINE; CEDIRANIB; CILENGITIDE; IRINOTECAN; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TALAMPANEL; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VINCRISTINE;

ANTIANGIOGENIC THERAPY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DNA METHYLATION; DRUG APPROVAL; DRUG POTENTIATION; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HUMAN; HYPERTENSION; IMMUNOMODULATION; KIDNEY DYSFUNCTION; LUNG EMBOLISM; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION; WOUND;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOMA; HUMANS;

EID: 76749157903     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0077-4     Document Type: Review

References (50)

1. Central Brain Tumor Registry of the United States (CBTRUS): 2008 statistical report: primary brain tumors in the United States. Available at http://www.cbtrus.org/reports/reports.html. Accessed November 2009.
2. R Stupp WP Mason MJ van den Bent, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D 15758009 (Pubitemid 40349501)
3. Stupp R, Hegi ME, Mason WP, et al.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466. This is the update of the original EORTC/NCIC study [2] that defined the standard of care for TMZ/RT with 5-year survival data.
4. M Khasraw D Bell H Wheeler 2009 Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? J Clin Neurosci 16 854 855 10.1016/j.jocn.2008.09.005 1:CAS:528:DC%2BD1MXltl2lu7c%3D 19303779
5. LE Abrey DN Louis N Paleologos, et al. 2007 Survey of treatment recommendations for anaplastic oligodendroglioma Neuro Oncol 9 314 318 10.1215/15228517-2007-002 1:CAS:528:DC%2BD2sXpt1agtr8%3D 17435180 (Pubitemid 47169664)
6. Wick W, Hartmann C, Engel C, et al.: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009 Nov 9 (Epub ahead of print).
7. Deangelis LM: Anaplastic gliomas. J Clin Oncol 2009 Nov 9 (Epub ahead of print). This editorial discusses two studies in anaplastic glioma, including Wick et al. [6].
8. M Preusser RC Janzer J Felsberg, et al. 2008 Anti-O6-Methylguanine- Methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker Brain Pathol 18 520 532 1:CAS:528:DC%2BD1cXht1CjtLvM 18400046
9. ME Hegi L Liu JG Herman, et al. 2008 Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity J Clin Oncol 26 4189 4199 10.1200/JCO.2007.11.5964 1:CAS:528:DC%2BD1cXhtFKisb7M 18757334
10. AA Brandes E Franceschi A Tosoni, et al. 2008 MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2192 2197 10.1200/JCO.2007.14.8163 18445844
11. ER Gerstner MB McNamara AD Norden, et al. 2009 Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression J Neurooncol 94 97 101 10.1007/s11060-009-9809-4 1:CAS:528:DC%2BD1MXotFWhsLs%3D 19221865
12. Brandsma D, Stalpers L, Taal W, et al.: (2008). Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008, 9:453-461. This is an excellent overview of pseudoprogression in GBM.
13. AA Brandes A Tosoni P Amista, et al. 2004 How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial Neurology 63 1281 1284 1:STN:280:DC%2BD2crgvVWntg%3D%3D 15477552
14. W Wick M Platten M Weller 2009 New (alternative) temozolomide regimens for the treatment of glioma Neuro Oncol 11 69 79 10.1215/15228517-2008-078 1:CAS:528:DC%2BD1MXjtFKntr8%3D 18772354
15. Lassman AB, Rossi MR, Raizer JJ, et al.: Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005, 11:7841-7850 (published correction appears in Clin Cancer Res 2006, 12:322).
16. IK Mellinghoff MY Wang I Vivanco, et al. 2005 Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2012 2024 10.1056/NEJMoa051918 1:CAS:528:DC%2BD2MXht1SrtrrE 16282176 (Pubitemid 41609094)
17. D Hanahan J Folkman 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 353 364 10.1016/S0092-8674(00) 80108-7 1:CAS:528:DyaK28XltVSks7s%3D 8756718 (Pubitemid 26272076)
18. AC Berger A Zalotoris DR Gugger JC Watson 2003 Mature circulating endothelial cells are increased in cancer patients receiving anti-angiogenic therapy J Am Coll Surgeons 197 S83 S84
19. DJ Hicklin 2005 Ellis, LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 1011 1027 10.1200/JCO.2005.06.081 1:CAS:528:DC%2BD2MXit1Gnsro%3D 15585754 (Pubitemid 46202320)
20. V Stark-Vance 2005 Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract 342] Neuro Oncol 7 369
21. TN Kreisl L Kim K Moore, et al. 2009 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 740 745 10.1200/JCO.2008.16.3055 1:CAS:528:DC%2BD1MXjsVCjs7o%3D 19114704
22. JJ Vredenburgh A Desjardins JE Herndon 2nd, et al. 2007 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 4722 4729 10.1200/JCO.2007.12.2440 1:CAS:528:DC%2BD2sXhtlCgsLjF 17947719 (Pubitemid 350086473)
23. Friedman HS, Prados MD, Wen PY, et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740. This is the study that led to accelerated approval by the US Food and Drug Administration of bevacizumab for recurrent GBM.
24. Weller M, Yung WK: Bevacizumab: news from the fast lane? Neuro Oncol 2008, 10:647. This excellent commentary discusses the nuances of antiangiogenic therapies and the use of irinotecan in recurrent glioma.
25. D Reardon A Desjardins J Vredenburgh, et al. 2008 Safety and efficacy of bevacizumab and metronomic, oral etoposide for recurrent glioblastoma patients in a phase II study Neuro Oncol 10 839
26. R Maron JJ Vredenburgh A Desjardins, et al. 2008 Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM) J Clin Oncol (Meeting Abstracts) 26 2074
27. PH Gutin FM Iwamoto K Beal, et al. 2009 Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas Int J Radiat Oncol Biol Phys 75 156 163 1:CAS:528: DC%2BD1MXhtVegsLjO 19167838
28. ML Gruber S Raza D Gruber A Narayana 2009 Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progression-free survival, overall survival, and toxicity J Clin Oncol (Meeting Abstracts) 27 2017
29. WJ Curran Jr CB Scott J Horton, et al. 1993 Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials J Natl Cancer Inst 85 704 710 10.1093/jnci/85.9.704 8478956
30. A Lai P Nghiemphu R Green, et al. 2009 Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme J Clin Oncol (Meeting Abstracts) 27 2000
31. A Lai E Filka B McGibbon, et al. 2008 Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability Int J Radiat Oncol Biol Phys 71 1372 1380 1:CAS:528:DC%2BD1cXoslWqsLo%3D 18355978
32. WB Pope A Lai P Nghiemphu, et al. 2006 MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy Neurology 66 1258 1260 10.1212/01.wnl.0000208958.29600.87 1:CAS:528:DC%2BD28XjtFOrtLs%3D 16636248 (Pubitemid 43739717)
33. FM Iwamoto LE Abrey K Beal, et al. 2009 Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma Neurology 73 1200 1206 10.1212/WNL.0b013e3181bc0184 1:CAS:528:DC%2BD1MXht1antrfK 19822869
34. W Chen S Delaloye DH Silverman, et al. 2007 Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol 25 4714 4721 10.1200/JCO.2006.10.5825 1:CAS:528:DC%2BD2sXhtlCgsLjL 17947718 (Pubitemid 350086472)
35. WB Pope HJ Kim J Huo, et al. 2009 Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment Radiology 252 182 189 10.1148/radiol.2521081534 19561256
36. EC Quant AD Norden J Drappatz, et al. 2009 Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab Neuro Oncol 11 550 555 10.1215/15228517-2009-006 1:CAS:528:DC%2BD1MXhtlWht73P 19332770
37. Batchelor TT, Sorensen AG, di Tomaso E, et al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95. This excellent translational study demonstrates changes in imaging and biologic parameters during treatment with the oral anti-VEGFR TKI cedirinib (AZD2171).
38. TV Byzova CK Goldman N Pampori, et al. 2000 A mechanism for modulation of cellular responses to VEGF: activation of the integrins Mol Cell 6 851 860 1:CAS:528:DC%2BD3cXnvVegtbo%3D 11090623
39. S Choi SA Lee TK Kwak, et al. 2009 Cooperation between integrin alpha5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity Blood 113 1845 1855 10.1182/blood-2008-05-160671 1:CAS:528:DC%2BD1MXisV2hs74%3D 19036703
40. JE Meredith Jr B Fazeli MA Schwartz 1993 The extracellular matrix as a cell survival factor Mol Biol Cell 4 953 961 1:CAS:528:DyaK2cXhtlSrsbo%3D 8257797
41. LB Nabors T Mikkelsen SS Rosenfeld, et al. 2007 Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma J Clin Oncol 25 1651 1657 10.1200/JCO.2006.06.6514 1:CAS:528:DC%2BD2sXlvFyktLY%3D 17470857 (Pubitemid 46797943)
42. DA Reardon KL Fink T Mikkelsen, et al. 2008 Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J Clin Oncol 26 5610 5617 10.1200/JCO.2008.16. 7510 1:CAS:528:DC%2BD1MXmsVSrsw%3D%3D 18981465
43. Stupp R, Goldbrunner R, Neyns B, et al.: (2007). Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol (Meeting Abstracts) 2007, 25:2000.
44. SA Grossman X Ye M Chamberlain, et al. 2009 Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial J Clin Oncol 27 4155 4161 10.1200/JCO.2008.21.6895 1:CAS:528:DC%2BD1MXhtF2jtLrI 19636006
45. N Butowski SM Chang L Junck, et al. 2009 A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05) J Neurooncol 91 175 182 10.1007/s11060-008-9693-3 1:CAS:528:DC%2BD1MXjvFeiuw%3D%3D 18797818
46. MR Rosenfeld M Chamberlain SA Grossman, et al. 2009 New Approaches to Brain Tumor Therapy: A CNS Consortium: A phase II study of chemoradiation followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma: 12- and 18-month survival data (NABTT 0501) J Clin Oncol (Meeting Abstracts) 27 2002
47. CJ Wheeler KL Black G Liu, et al. 2008 Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients Cancer Res 68 5955 5964 10.1158/0008-5472.CAN-07-5973 1:CAS:528:DC%2BD1cXovVCntrg%3D 18632651
48. Heimberger AB, Archer GE, Mitchell DA, et al.: (2009). Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM. J Clin Oncol (Meeting Abstracts) 2009, 27:2021.
49. MJ van den Bent MA Vogelbaum PY Wen, et al. 2009 End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria J Clin Oncol 27 2905 2908 10.1200/JCO.2009.22.4998 19451418
50. Grossman SA, Ye X, Piantadosi S, et al.: Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States [abstract]. J Clin Oncol 2009, 27:2003. This meeting abstract provides an interesting analysis of the survival statistics in recently presented trials for newly diagnosed glioblastoma.